Contract Award

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce a new contract with its long-standing client, Numab Therapeutics AG.

The project will involve the application of modelling and simulation techniques to inform pre-clinical development of a multi-specific antibody designed to activate anti-tumor immune responses for the treatment of cancer. This project is expected to complete within the next two months.

This latest collaboration extends the history of the Company working with Numab Therapeutics in applying Model Informed Drug Development to address complex challenges with mathematical modelling and simulation techniques.

Dr Peter Sargent, CEO of Physiomics, commented:

"This new contract marks another step in our long-term collaboration with Numab Therapeutics, reinforcing our role as a trusted partner to provide specialist modelling support to inform critical stages of drug development. We are delighted to be working once again with the Numab team."

For more information about Physiomics and its services, please visit www.physiomics.co.uk.